Selective serotonin reuptake inhibitor
A piperidine SSRI with the highest SERT affinity in the class and clinically significant muscarinic antagonism.
Abstract
Paroxetine ((3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; CAS 61869-08-7; molecular formula C19H20FNO3; molecular weight 329.36) is a phenylpiperidine SSRI developed at Ferrosan and licensed to SmithKline Beecham (now GSK), approved by the FDA in 1992 under the trade name Paxil. SERT affinity is the highest of any SSRI (Ki approximately 0.13 nM); off-target activity at muscarinic acetylcholine receptors (Ki approximately 100 nM) produces sedation and dry mouth at clinical doses, and weak NET inhibition contributes to noradrenergic effects at higher doses. Plasma half-life is approximately 21 hours with significant interpatient variability driven by CYP2D6 polymorphism (paroxetine is both a substrate and a potent inhibitor of CYP2D6, producing nonlinear pharmacokinetics at high doses). The compound exhibits the most pronounced discontinuation syndrome of the SSRI class, attributed to the relatively short half-life and muscarinic rebound on cessation. Used as a high-affinity SERT reference compound in receptor binding assays and as a comparator in OCD and anxiety disorder research.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.